Key Takeaways
- Eli Lilly’s innovative triple-receptor drug retatrutide successfully completed its initial Phase 3 trial in Type 2 diabetes
- HbA1c levels decreased by 1.7%–2% compared to placebo’s 0.8% reduction over 40 weeks
- Participants achieved up to 16.8% body weight reduction on the maximum dosage
- The drug activates three hormones (GLP-1, GIP, glucagon) compared to competitors’ one or two targets
- FDA filing pending; seven additional Phase 3 studies expected to report findings by 2025 year-end
Eli Lilly revealed Thursday that retatrutide, its investigational diabetes treatment, successfully achieved primary endpoints in its inaugural late-stage clinical trial, demonstrating significant blood glucose reduction and substantial weight loss among Type 2 diabetes participants.
The study spanned 40 weeks and enrolled Type 2 diabetes patients controlling their condition solely through lifestyle modifications including diet and physical activity. Participants began the trial with HbA1c measurements ranging from 7% to 9.5%.
Across different dosing levels, retatrutide achieved HbA1c reductions averaging between 1.7% and 2%, significantly outpacing the placebo group’s 0.8% decrease. This outcome satisfied the study’s principal objective.
Regarding body weight outcomes, participants receiving the maximum dose experienced an average reduction of 16.8% when analyzing only those who completed treatment. Including all enrolled participants—even those who discontinued—the average loss reached 15.3%.
By comparison, Lilly’s approved medication Zepbound produced weight reductions between 11% and 13.1% in similar 40-week diabetes trials. While retatrutide’s results appear superior, direct comparative studies haven’t been conducted.
Louise Chen, an analyst with Scotiabank, characterized the results as “the highest levels of weight loss we’ve seen from an obesity drug to date” among a patient population known for weight loss challenges.
Analysts from J.P. Morgan provided a more cautious assessment, pointing out that the drug’s benefits must be weighed against elevated adverse event frequencies compared to Lilly’s diabetes medication Mounjaro.
Retatrutide’s Mechanism of Action
Retatrutide functions as a weekly injectable that stimulates three distinct hormone receptors—GLP-1, GIP, and glucagon—giving it the designation “triple-G.” This represents one additional target compared to Zepbound (tirzepatide), which activates GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which solely activates GLP-1.
The therapeutic strategy involves simultaneously targeting all three biological pathways to reduce appetite, regulate glucose levels, and enhance metabolic rate.
Adverse reactions were predominantly digestive in nature. Approximately 26.5% of maximum-dose participants reported nausea, 22.8% experienced diarrhea, and 17.6% had vomiting episodes. Treatment discontinuation due to adverse effects reached a maximum of 5%, which Lilly characterized as comparatively modest.
A limited number of participants developed dysesthesia—an uncomfortable nerve-related sensation.
Regulatory Pathway Forward
Lilly hasn’t submitted regulatory applications for retatrutide approval in either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 data release for this compound.
The pharmaceutical company anticipates receiving data from seven more Phase 3 trials throughout 2025, encompassing diverse patient demographics.
Lilly is simultaneously preparing for the anticipated Q2 2025 launch of orforglipron, its oral obesity medication, contingent on FDA clearance.
Meanwhile, Novo Nordisk is pursuing competitive advantages. During March 2025, Novo acquired rights to a triple-receptor compound from United Laboratories International for up to $2 billion—though this candidate remains in preliminary development stages and won’t reach patients for several years.
Lilly stock (LLY) experienced modest premarket declines Thursday following the trial results announcement.
